Israeli biotech Senseera raises $7.1 million Seed round for liquid biopsy platform
Israeli biotech Senseera raises $7.1 million Seed round for liquid biopsy platform
The GEM BIOMARKERS technology aims to revolutionize diagnostics in oncology, immunology, and liver disease management.
Jerusalem-based biotech company Senseera has closed a $7.1 million Seed funding round led by Lightspeed Venture Partners, with participation from I-Next Capital and the Lowy Medical Research Institute. The funds will be used to advance the company’s GEM BIOMARKERS liquid biopsy platform, which promises to transform disease diagnostics and monitoring by offering biopsy-level precision through a simple blood test.
Senseera’s platform leverages cfChIP-seq technology to decode cell-specific gene expression and cell states from blood samples. This innovation could significantly improve the diagnosis and management of conditions such as liver diseases, oncology, immunology, and metabolic disorders. Current diagnostic tools for liver diseases, which affect up to 25% of the global population, often rely on invasive procedures or nonspecific tests, leading to delayed diagnoses and poor patient care. Senseera aims to address these gaps with its non-invasive platform, offering early detection and improved monitoring for conditions such as MASLD/MASH (formerly NAFLD/NASH), liver transplant rejection, and hepatocellular carcinoma (HCC).
The funding will enable Senseera to accelerate the clinical development of its next-generation liver transplant rejection test, conduct additional clinical trials, and expand partnerships with global biopharma companies. The company also sees its platform as a tool for advancing drug development, particularly in cancer and immune disorders, by providing insights into the interactions between solid tissues and immune cells.
“This funding marks a major milestone in Senseera’s journey to transform diagnostics for liver diseases and beyond,” said Dr. Ronen Sadeh, CEO of Senseera. “With the support from Lightspeed and our investors, we will advance clinical trials, strengthen collaborations with global pharma leaders, and expand our pipeline to improve patient outcomes.”
Senseera’s work builds on decades of research led by Prof. Nir Friedman, with findings published in high-profile journals such as Nature Biotechnology. Data from over 20,000 human samples underpins the company’s technology.
